Infinitopes
↗Oxford, United Kingdom
Infinitopes is a clinical-stage, integrated cancer biotechnology company and CRUK-led spinout from Oxford University founded in September 2021. The company combines precision antigen discovery and high-efficiency viral vector delivery systems to develop immunologically durable vaccines targeting multiple solid tumor indications. Using its proprietary Precision Immunomics™ platform powered by AI/ML workflows, Infinitopes identifies tumor-specific peptides and delivers them via a durable viral vector, enabling oncologists to provide post-surgical relapse prevention therapies. The company has rapidly scaled from three academic co-founders to 28 full-time employees and serves as the largest tenant of Oxford University's BioEscalator innovation accelerator.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:~£12.8M (approximately $16.1M USD)
Investors:Octopus Ventures (lead), Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, Caffeinated Capital, EMV Capital, Expert angel investors
PIPELINE
Stage:Phase 1/IIa
Lead Drug Stage:Phase I/IIa Clinical Trial
Modalities:Viral Vector Vaccines, Personalized Cancer Vaccines
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:University of Oxford (IP licensing and research collaboration), Cancer Research UK (institutional support and funding), UK NHS Cancer Centers (VISTA trial sites)
COMPETITION
Position:Emerging
Competitors:Moderna, BeiGene, Juno Therapeutics, BioNTech, CureVac, Candel Therapeutics, Nouscom, Azalea Therapeutics +1 more
LEADERSHIP
Key Executives:
Jonathan Kwok - Chief Executive Officer & Co-Founder
Dr. Lian Ni Lee - Laboratory Lead
Dr. Senthil Chinnakannan - Co-Founder
Dan Menichella - Non-Executive Director
Jo Brewer, PhD - Non-Executive Director
Prof. Mark Middleton - Chief Investigator (VISTA Trial)
Scientific Founders:Prof. Paul Klenerman (University of Oxford) - Antigen discovery and T-cell immunology, Assoc. Prof. Nicola Ternette (University of Oxford) - Immunopeptidomics and antigen discovery, Prof. Mark Middleton (University of Oxford) - Clinical oncology leadership
Board Members:Jonathan Kwok (CEO), Dan Menichella (Non-Executive Director), Jo Brewer, PhD (Non-Executive Director)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Infinitopes. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.